Clinicopathological, therapeutic and prognostic features of the triple-negative tumors in moroccan breast cancer patients (experience of Hassan II university hospital in Fez)

BMC Research Notes

Volumn 4, Issue , 2011, Pages

  Akasbi, Yousra ^a   Bennis, Sanae ^a,b   Abbass, Fouad ^a,c   Znati, Kawtar ^a   Joutei, Khalid ^c   Amarti, Afaf ^a   Mesbahi, Omar E L ^a  

^a HASSAN II UNIVERSITY HOSPITAL   (Morocco)

^b SIDI MOHAMED BEN ABDELLAH UNIVERSITY   (Morocco)

^c SIDI MOHAMED BEN ABDELLAH UNIVERSITY   (Morocco)

Author keywords

Clinico pathological; Prognostic features; Triple negative breast cancer

Indexed keywords

EID: 81055148296     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/1756-0500-4-500     Document Type: Article

References (25)

1. Molecular classification and molecular forecasting of breast cancer: ready for clinical application? Brenton JD, Carey LA, Ahmed AA, Caldas C, J Clin Oncol 2005 23 7350 7360 10.1200/JCO.2005.03.3845 16145060 (Pubitemid 46202348)
2. Molecular portraits of human breast tumours. Perou CM, Sørlie T, Eisen MB, Mvan de Rijn M, Jeffreyk SS, Rees CA, et al. Nature 2000 406 747 52 10.1038/35021093 10963602
3. Basal-like breast cancer: a critical review. Rakha EA, Reis-Filho JS, Ellis IO, J Clin Oncol 2008 26 2568 2581 10.1200/JCO.2007.13.1748 18487574
4. Locoregional relapse and distant metastasis inconservatively managed triple negative early-stage breast cancer. Haffty BG, Yang Q, Reiss M, Kearney T, Higgins SA, Weidhaas J, et al. J Clin Oncol 2006 24 5652e7
5. Triple-negative breast cancer: clinical features and patterns of recurrence. Dent R, Trudeau M, Pritchard KI, et al. Clin Cancer Res 2007 13 4429e34
6. Repeated observation of breast tumor subtypes in independent gene expression data sets. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al. ProcNatl Acad Sci USA 2003 100 8418 8423 10.1073/pnas.0932692100 (Pubitemid 36842560)
7. Hallmarks of 'BRCAness' in sporadic cancers. Turner N, Tutt A, Ashworth A, Nat Rev Cancer 2004 4 814 819 10.1038/nrc1457 15510162 (Pubitemid 39331153)
8. Germline BRCA1 mutations and a basal epithelial phenotypein breast cancer. Foulkes WD, Stefansson IM, Chappuis PO, Bégin LR, Goffin JR, Wong N, et al. J Natl Cancer Inst 2003 95 1482 1485 10.1093/jnci/djg050 14519755 (Pubitemid 37279334)
9. Incidence and outcome of BRCA mutations inunselected patients with triple receptor-negative breast cancer. Gonzalez-Angulo AM, Timms KM, Liu S, Chen H, Litton JK, Potter J, et al. Clin Cancer Res 2011 17 1082 1089 10.1158/1078-0432.CCR-10-2560 21233401
10. Poly(ADP-ribose) polymerase inhibition: targeted therapy for triple negative breast cancer. Anders CK, Winer EP, Ford JM, Dent R, Silver DP, Sledge GW, et al. Clin Cancer Res 2010 16 4702 4710 10.1158/1078-0432.CCR-10-0939 20858840
11. Inhibition of poly(ADP-ribose) polymerase intumors from BRCA mutation carriers. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, et al. N Engl J Med 2009 361 123 134 10.1056/NEJMoa0900212 19553641
12. Race and the poor prognosis basal-like breast cancer (BBC) phenotype in the population-based Carolina breast cancer study. Carey LA, Perou CM, Dressler LG, Livasy C, Geradts J, Cowan D, et al. J Clin Oncol 2004 (suppl; abstr 9510)
13. Race, breast cancer subtypes, and survival in the Carolina breast cancer study. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, et al. J Am Med Assoc 2006 295 2492 2502 10.1001/jama.295.21.2492 (Pubitemid 43854964)
14. Ethnicity and breast cancer: factors influencing differences in incidence and outcome. Chlebowski RT, Chen Z, Anderson GL, Rohan T, Aragaki A, Lane D, Dolan NC, Paskett PA, et al. J Natl Cancer Inst 2005 97 439 448 10.1093/jnci/dji064 15770008 (Pubitemid 40528607)
15. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Livasy CA, Karaca G, Nanda R, Tretiakova MS, Olopade OI, Moore DT, Perou CM, Mod Pathol 2006 19 264 271 10.1038/modpathol.3800528 16341146 (Pubitemid 43117611)
16. Molecular classification of breast carcinomas by immunohistochemical analysis. Tang P, Skinner KA, Hicks DG, Diagn Mol Pathol 2009 18 125 132 10.1097/PDM.0b013e31818d107b 19704256
17. T1N0 triple negative breast cancer: adjuvant chemotherapy treatment and risk of recurrence. Kaplan HG, Malmgren JA, Atwood MK, Presented at the 30th Annual San Antonio Breast Cancer Symposium; December13-16, 2007; San Antonio, TX 3070
18. Breast cancer molecular subtypes respond differently to pre-operative chemotherapy. Rouzier R, Perou CM, Symmans WF, Nuhad I, Cristofani M, Anderson K, et al. Clin Cancer Res 2005 11 5678 5685 10.1158/1078-0432.CCR-04-2421 16115903 (Pubitemid 41170290)
19. Molecular classification system identifies invasive breast carcinoma patients who are most likely and those who are least likely to achieve a complete pathologic response after neoadjuvant chemotherapy. Goldstein S, Decker D, Severson D, Schell S, Vicini F, Margolis J, Dekhne NS, Cancer 2007 110 1687 1696 10.1002/cncr.22981 17722109 (Pubitemid 47557293)
20. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, et al. Clin Cancer Res 2007 13 2329 2334 10.1158/1078-0432.CCR-06-1109 17438091 (Pubitemid 46698581)
21. Vascular endothelial growth factor expression in the basal subtype of breast carcinoma. Ribeiro-Silva A, do Vale FR, Zucoloto, Am J Clin Pathol 2006 125 512 518 16627261
22. KIT (CD117)-positive breast cancers are infrequent and lack KIT gene mutations. Simon R, Panussis S, Maurer R, et al. Clin Cancer Res 2004 10 178 183 10.1158/1078-0432.CCR-0597-3 14734467 (Pubitemid 38114177)
23. A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer. Modi S, Seidman AD, Dickler R, Moasser M, D'Andrea G, Moynahan ML, et al. Breast Cancer Res Treat 2005 90 157 163 10.1007/s10549-004- 3974-0 15803362
24. Cell-type-specific responses to chemotherapeutics in breast cancer. Troester MA, Hoadley KA, Sorlie T, Herbert B, Børresen-Dale AL, Lønning PE, et al. Cancer Res 2004 64 4218 4226 10.1158/0008-5472.CAN-04- 0107 15205334 (Pubitemid 38802426)
25. Prognostic value of the X-linked inhibitor of apoptosis protein for invasive ductal breast cancer with triple-negative phenotype. Wang Jinjing, Liu Yixin, Ru Ji MS, Qiang Gu BS, Xiulan Zhao BS, Yanrong Liu MS, Sun Baocun, Hum Pathol 2010 41 8 1186 1195 Epub 2010 Apr 10 10.1016/j.humpath.2010.01.013 20381828